Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Rosario DJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 41
Tytuł:
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Autorzy:
Greasley R
Khabazhaitajer M
Rosario DJ
Pokaż więcej
Temat:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Cancer Management and Research, Vol 2015, Iss default, Pp 153-164 (2015)
Opis pliku:
electronic resource
Relacje:
http://www.dovepress.com/a-profile-of-enzalutamide-for-the-treatment-of-advanced-castration-res-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
Dostęp URL:
https://doaj.org/article/aa26059002c5485b9a7da7297640cb19  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Autorzy:
Lane JA; Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Medical School, Bristol Trials Centre, University of Bristol, Bristol, UK.
Donovan JL; Bristol Medical School, University of Bristol, Bristol, UK.
Young GJ; Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Medical School, Bristol Trials Centre, University of Bristol, Bristol, UK.
Davis M; Bristol Medical School, University of Bristol, Bristol, UK.
Walsh EI; Bristol Medical School, University of Bristol, Bristol, UK.
Avery KNL; Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Medical School, NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.
Blazeby JM; Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Medical School, NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.
Mason MD; School of Medicine, Cardiff University, Cardiff, UK.
Martin RM; Bristol Medical School, University of Bristol, Bristol, UK.; Bristol Medical School, NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.
Peters TJ; Bristol Medical School, University of Bristol, Bristol, UK.
Turner EL; Bristol Medical School, University of Bristol, Bristol, UK.
Wade J; Bristol Medical School, University of Bristol, Bristol, UK.
Bollina P; Department of Urology and Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK.
Catto JWF; Academic Urology Unit, University of Sheffield, Sheffield, UK.
Doherty A; Department of Urology, Queen Elizabeth Hospital, Birmingham, UK.
Gillatt D; Department of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK.
Gnanapragasam V; Department of Urology, Addenbrooke's Hospital, Cambridge, UK.
Hughes O; Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
Kockelbergh R; Department of Urology, University Hospitals of Leicester, Leicester, UK.
Kynaston H; Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
Oxley J; Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK.
Paul A; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Paez E; Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK.
Rosario DJ; Academic Urology Unit, University of Sheffield, Sheffield, UK.
Rowe E; Department of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK.
Staffurth J; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Neal DE; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Hamdy FC; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust and University of Oxford, UK.
Metcalfe C; Bristol Medical School, University of Bristol, Bristol, UK.
Pokaż więcej
Corporate Authors:
Prostate Testing for Cancer and Treatment (ProtecT) Study Group
Źródło:
BJU international [BJU Int] 2022 Sep; Vol. 130 (3), pp. 370-380. Date of Electronic Publication: 2022 May 03.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Brachytherapy*
Erectile Dysfunction*
Prostatic Neoplasms*/pathology
Aged ; Androgen Antagonists ; Humans ; Male ; Middle Aged ; Prostate/pathology ; Prostatectomy ; Quality of Life ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial).
Autorzy:
Reale S; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Turner RR; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Sutton E; Population Health Sciences, University of Bristol, Bristol, UK.
Steed L; Institute for Population Health Sciences, Queen Mary University of London, London, UK.
Taylor SJC; Institute for Population Health Sciences, Queen Mary University of London, London, UK.
Morrissey D; Sports and Exercise Medicine, School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, UK.
Doherty P; Department of Health Sciences, University of York, York, UK.
Greenfield DM; Specialised Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
Collinson M; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Hewison J; School of Medicine, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Brown J; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Ibeggazene S; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Mason M; School of Medicine, Cardiff University, Cardiff, UK.
Rosario DJ; Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK.
Bourke L; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jun 14; Vol. 11 (1), pp. 12470. Date of Electronic Publication: 2021 Jun 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Exercise*
Prostatic Neoplasms/*pathology
Aged ; Androgen Antagonists/therapeutic use ; Attitude ; Cohort Studies ; Feasibility Studies ; Humans ; Life Style ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Prostatic Neoplasms/drug therapy ; Resistance Training
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial.
Autorzy:
Turner RR; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Arden MA; Centre for Behavioural Science and Applied Psychology (CeBSAP), Sheffield Hallam University, Sheffield, UK.
Reale S; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Sutton E; Population Health Sciences, University of Bristol, Bristol, UK.
Taylor SJC; Institute for Population Health Sciences, Queen Mary, University of London, London, UK.
Bourke L; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Greenfield DM; Specialised Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Morrissey D; Sports and Exercise Medicine, William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary, University of London, London, UK.; Physiotherapy Department, Barts Health NHS Trust, London, UK.
Brown J; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Doherty P; Department of Health Sciences, University of York, York, UK.
Rosario DJ; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.; Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK.
Steed L; Institute for Population Health Sciences, Queen Mary, University of London, London, UK. .
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2021 Mar 25; Vol. 21 (1), pp. 273. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/therapy
Quality of Life*
Androgen Antagonists ; Delivery of Health Care ; Evidence-Based Medicine ; Humans ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Towards implementing exercise into the prostate cancer care pathway: development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial).
Autorzy:
Reale S; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Turner RR; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Sutton E; Population Health Sciences, University of Bristol, Bristol, UK.
Taylor SJC; Institute for Population Health Sciences, Queen Mary University of London, London, UK.
Bourke L; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.
Morrissey D; Sports and Exercise Medicine, William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Brown J; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Rosario DJ; Allied Health Professionals, Radiotherapy and Oncology, Sheffield Hallam University, Sheffield, UK.; Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK.
Steed L; Institute for Population Health Sciences, Queen Mary University of London, London, UK. .
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2021 Mar 22; Vol. 21 (1), pp. 264. Date of Electronic Publication: 2021 Mar 22.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Androgen Antagonists*
Prostatic Neoplasms*/therapy
Evidence-Based Medicine ; Exercise ; Focus Groups ; Humans ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
Autorzy:
Bryant RJ; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Oxley J; Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK.
Young GJ; Bristol Medical School, University of Bristol, Bristol, UK.; The Bristol Randomised Trials Collaboration, University of Bristol, Bristol, UK.
Lane JA; Bristol Medical School, University of Bristol, Bristol, UK.; The Bristol Randomised Trials Collaboration, University of Bristol, Bristol, UK.
Metcalfe C; Bristol Medical School, University of Bristol, Bristol, UK.; The Bristol Randomised Trials Collaboration, University of Bristol, Bristol, UK.
Davis M; Bristol Medical School, University of Bristol, Bristol, UK.
Turner EL; Bristol Medical School, University of Bristol, Bristol, UK.
Martin RM; Bristol Medical School, University of Bristol, Bristol, UK.
Goepel JR; Department of Pathology, Royal Hallamshire Hospital, Sheffield, UK.
Varma M; Department of Pathology, University Hospital of Wales, Cardiff, UK.
Griffiths DF; Department of Pathology, University Hospital of Wales, Cardiff, UK.
Grigor K; Department of Pathology, Western General Hospital, Edinburgh, UK.
Mayer N; Department of Pathology, University of Leicester, Leicester, UK.
Warren AY; Department of Pathology, University of Cambridge, Cambridge, UK.
Bhattarai S; Department of Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Dormer J; Department of Pathology, University of Leicester, Leicester, UK.
Mason M; School of Medicine, Cardiff University, Cardiff, UK.
Staffurth J; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Walsh E; Bristol Medical School, University of Bristol, Bristol, UK.
Rosario DJ; Academic Urology Unit, University of Sheffield, Sheffield, UK.
Catto JWF; Academic Urology Unit, University of Sheffield, Sheffield, UK.
Neal DE; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; Academic Urology Group, University of Cambridge, Cambridge, UK.
Donovan JL; Bristol Medical School, University of Bristol, Bristol, UK.; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Hamdy FC; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Pokaż więcej
Corporate Authors:
ProtecT Study Group
Źródło:
BJU international [BJU Int] 2020 Apr; Vol. 125 (4), pp. 506-514. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms/*pathology
Aged ; Cohort Studies ; Disease Progression ; Follow-Up Studies ; Humans ; Kallikreins/blood ; Male ; Middle Aged ; Neoplasm Staging ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Risk Assessment ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Autorzy:
Bancroft EK; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Saya S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Page EC; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Myhill K; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Thomas S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Pope J; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Chamberlain A; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Hart R; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
Glover W; Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
Rosario DJ; Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Helfand BT; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
Hutten Selkirk C; John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
Davidson R; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
Longmuir M; Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
Eccles DM; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.; Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Gadea N; High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona, Spain.
Brewer C; Clinical Genetics Department, Royal Devon and Exeter Hospital, Exeter, UK.
Barwell J; Department of Genetics, University of Leicester, Leicester, UK.; Clinical Genetics, University Hospitals Leicester, Leicester, UK.
Salinas M; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain.
Greenhalgh L; Cheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool, UK.
Tischkowitz M; Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK.
Henderson A; Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle, UK.
Evans DG; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Buys SS; Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
Eeles RA; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.
Aaronson NK; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors:
IMPACT Study Steering Committee
IMPACT Collaborators
Źródło:
BJU international [BJU Int] 2019 Feb; Vol. 123 (2), pp. 284-292. Date of Electronic Publication: 2018 Jun 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genes, BRCA1*
Genes, BRCA2*
Early Detection of Cancer/*psychology
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*psychology
Adult ; Anxiety/etiology ; Case-Control Studies ; Depression/etiology ; Health Knowledge, Attitudes, Practice ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Mutation ; Perception ; Prostatic Neoplasms/diagnosis ; Psychiatric Status Rating Scales ; Quality of Life ; Risk Factors ; Surveys and Questionnaires
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS.
Autorzy:
Bourke L; Health and Wellbeing, Sheffield Hallam University, Sheffield United Kingdom.
Turner R; Health and Wellbeing, Sheffield Hallam University, Sheffield United Kingdom.
Greasley R; Health and Wellbeing, Sheffield Hallam University, Sheffield United Kingdom.
Sutton E; School of Social and Community Medicine, University of Bristol, Bristol United Kingdom.
Steed L; Centre for Primary Care and Public Health, Queen Mary University of London, London United Kingdom.
Smith D; Department of Geography and Environment, University of Southampton, Southampton United Kingdom.
Brown J; Department of Oncology and Metabolism, University of Sheffield, Sheffield United Kingdom.
Kelly B; Nuffield Health Research Group, Epsom Gateway, Epsom, Surrey United Kingdom.
Hulme C; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds United Kingdom.
Greenfield D; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield United Kingdom.
Persad R; Department of Urology/Surgery, Southmead Hospital, Bristol, United Kingdom.
Farrin A; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds United Kingdom.
Hewison J; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds United Kingdom.
Rosario DJ; Department of Oncology and Metabolism, University of Sheffield, Sheffield United Kingdom.
Pokaż więcej
Corporate Authors:
STAMINA investigators
Źródło:
PloS one [PLoS One] 2018 Jul 05; Vol. 13 (7), pp. e0197606. Date of Electronic Publication: 2018 Jul 05 (Print Publication: 2018).
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Guidelines as Topic*
Exercise Therapy/*methods
Prostatic Neoplasms/*therapy
Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Prostate/physiopathology ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/pathology ; Quality of Life ; Surveys and Questionnaires ; United Kingdom
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.
Autorzy:
Greasley RU; The Centre for Sport and Exercise Science, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.
Turner R; The Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.
Collins K; Centre for Health and Social Care Research, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.
Brown J; Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Sheffield, UK.
Bourke L; The Centre for Sport and Exercise Science, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK. .
Rosario DJ; The Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Jun 19; Vol. 18 (1), pp. 667. Date of Electronic Publication: 2018 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Health Knowledge, Attitudes, Practice*
Health Personnel*
Prostatic Neoplasms, Castration-Resistant/*therapy
Humans ; Interviews as Topic ; Male ; Medical Oncology/methods ; Medical Oncology/trends
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 41

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies